Obstructive Sleep Apnea in Bronchiectasis: Prevalence, Risk Factors and Clinical Implications-A Systematic Review and Meta-Analysis
Abstract
Obstructive sleep apnea (OSA) has been poorly characterised in patients with bronchiectasis despite potential bidirectional clinical impacts. This systematic review and meta-analysis determined the prevalence of OSA confirmed by polysomnography in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. A comprehensive search of MEDLINE, EMBASE and Cochrane databases through September 2025 identified observational studies reporting polysomnography-confirmed OSA prevalence in adult bronchiectasis patients. Five studies encompassing 256 patients met inclusion criteria, with data extracted and quality assessed using the Newcastle-Ottawa Scale. The pooled obstructive sleep apnea prevalence was 50.5% (95% confidence interval: 42.3%-58.9%) with low heterogeneity, ranging from 40.4% to 64.3% in cystic fibrosis patients and 40.8% to 55.8% in non-cystic fibrosis bronchiectasis patients. Traditional risk factors including obesity and excessive daytime sleepiness showed weak associations, with a mean body mass index of 23.8-24.2 kg/m2. Male gender, longer disease duration, and corticosteroid use emerged as significant risk factors. Nocturnal hypoxemia independent of obstructive sleep apnea occurred in 16.7% of patients. Only 41% of diagnosed patients received positive airway pressure therapy. OSA affects approximately half of all bronchiectasis patients regardless of aetiology, substantially exceeding general population rates. The clinical presentation differs from classical…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 256 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.